Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Near Universal National Uptake of Dexrazoxane in the Real-World Setting Associated with Reduced Cardiac ICU Care Requirements in Pediatric Acute Myeloid Leukemia

Daniel J. Zheng, Gary Hettinger, Lusha Cao, Caitlin W. Elgarten, Brian T. Fisher, Cody Gathers, Yuan-Shung V. Huang, Jennifer Ko, Kasey Leger, Yimei Li, Regina M. Myers, Hari K. Narayan, Jose Ortiz, Alix E. Seif, Richard Aplenc, Kelly D. Getz

Blood (2024) 144 (Supplement 1): 116.

https://doi.org/10.1182/blood-2024-208120

Published: 2024

Journal Articles

Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 531.

https://doi.org/10.1182/blood-2024-198385

Published: 2024

Journal Articles

Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

Regina M. Myers, Yimei Li, Adam Lamble, Emily M. Hsieh, Samuel John, Gregory Dolan, Hongyan Liu, Lee Chen, Jennifer Sheppard, Amanda M. DiNofia, Colleen Annesley, Stephan A. Grupp, Deepa Bhojwani, Rebecca A. Gardner, Lia Gore, Susan R Rheingold, Nirali N. Shah, Michael A. Pulsipher

Blood (2024) 144 (Supplement 1): 4827.

https://doi.org/10.1182/blood-2024-202027

Published: 2024

Journal Articles

Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123

Saamia Farooki, Han R Fisher, Anand S Bhagwat, Tina Glisovic-Aplenc, Lusha Cao, Regina M. Myers, Haley Newman, Caroline Diorio, Saar Gill, Richard Aplenc

Blood (2024) 144 (Supplement 1): 2946.

https://doi.org/10.1182/blood-2024-201034

Published: 2024

Journal Articles

Preinfusion Risk Factors for the Development of Severe Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Infusion in Pediatric Patients

Caroline Diorio, Regina M. Myers, Yimei Li, Amanda M. Dinofia, Hongyan Liu, Allison Barz Leahy, Haley Newman, Jillian Dolan, Zachary Martinez, Amira Elhachimi, Cassidy Mullen, Alexander Lai Li, John Kim, David T. Teachey, Shannon L. Maude, Jennifer McGuire, Stephan A. Grupp

Blood (2024) 144 (Supplement 1): 3454.

https://doi.org/10.1182/blood-2024-204993

Published: 2024

Journal Articles

In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing

Blood (2024) 144 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2024-210324

Published: 2024

Journal Articles

Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform

Allison Barz Leahy, Jennifer Brogdon, Lucy Cain, Amanda M. Dinofia, Joseph A. Fraietta, Richard Hanna, Stephan Kadauke, Raabia Khan, Yimei Li, Shannon L. Maude, Regina M. Myers, Laura Shinehouse, Anna Sparrow, Melissa Varghese, Lei Wang, Yongping Wang, Stephan A. Grupp

Blood (2024) 144 (Supplement 1): 3470.

https://doi.org/10.1182/blood-2024-204300

Published: 2024

Journal Articles

Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents

Caroline Diorio, Laura Hernandez-Miyares, Diego A. Espinoza, Brenda L. Banwell, Amit Bar-Or, Amanda M. DiNofia, Allison Barz Leahy, Zachary Martinez, Regina M. Myers, Sarah E. Hopkins, Susan R. Rheingold, David T. Teachey, Angela N. Viaene, Lisa M. Wray, Shannon L. Maude, Stephan A. Grupp, Jennifer L. McGuire

Blood (2024) 144 (13): 1387–1398.

https://doi.org/10.1182/blood.2024023933

Published: 2024

Includes: Supplemental data

Journal Articles

Survival Disparities By Frontline Clinical Trial Enrollment Status for Treatment of Pediatric Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2430.

https://doi.org/10.1182/blood-2023-189240

Published: 2023

Journal Articles

Comparative Effectiveness of Reinduction Approaches for Pediatric Relapsed Acute Myeloid Leukemia

Caitlin W. Elgarten, Regina M. Myers, Alix E. Seif, Yimei Li, Daniel J. Zheng, Naomi J Winick, Elaine Morgan, Rajen Mody, Arunkumar Modi, Tamara P. Miller, Kelly Maloney, Mallorie M. Heneghan, M. Monica Gramatges, Brian T. Fisher, Kelly D. Getz, Richard Aplenc

Blood (2023) 142 (Supplement 1): 551.

https://doi.org/10.1182/blood-2023-188044

Published: 2023

Journal Articles

Establishing Real-World Data-Driven Response Criteria in Pediatric Acute Myeloid Leukemia

Richard Aplenc, Yimei Li, Julianne Ani, Caitlin W. Elgarten, Lisa D'Errico, Todd Cooper, E. Anders Kolb, Maria Monica Gramatges, Meret Henry, Tamara P. Miller, Rajen Mody, Elaine Morgan, Regina M. Myers, Jessica A. Pollard, Alix Seif, Brian T. Fisher, Kelly D. Getz

Blood (2023) 142 (Supplement 1): 726.

https://doi.org/10.1182/blood-2023-185647

Published: 2023

Journal Articles

Outcomes and Toxicities after Allogeneic Hematopoietic Cell Transplant for Remission Consolidation or Relapse Therapy after CD19 Chimeric Antigen Receptor T Cell Therapy in Children and Young Adults with Acute Lymphoblastic Leukemia

Regina M. Myers, Sarah Mumanachit, Shannon L. Maude, Amanda M. Dinofia, Jason L. Freedman, Nancy Bunin, Lisa Wray, Allison Barz Leahy, Timothy S Olson, Stephan Grupp, Alix E. Seif, Caitlin W. Elgarten

Blood (2023) 142 (Supplement 1): 3767.

https://doi.org/10.1182/blood-2023-188047

Published: 2023

Journal Articles

Racial and Ethnic Differences in Acuity and Cumulative Frontline Organ Toxicity at the Time of Relapse in Pediatric Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 387.

https://doi.org/10.1182/blood-2023-180713

Published: 2023

Journal Articles

IL-10 Levels Differentially Regulate IFNg Signaling of CART19 and CART22

Caroline Diorio, Regina M. Myers, Anastasia Frank-Kamenetski, Rawan Shraim, Amanda M. Dinofia, Zachary Martinez, Ohaila Mustafa, Joseph A Fraietta, Vanessa Gonzalez, Vivian Yi, Lahari Uppuluri, Haley Newman, Edward Behrens, Carl June, Scott Canna, Stephan Grupp, David T. Teachey

Blood (2023) 142 (Supplement 1): 3431.

https://doi.org/10.1182/blood-2023-182377

Published: 2023

Journal Articles

How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL

Regina M. Myers, Nirali N. Shah, Michael A. Pulsipher

Blood (2023) 141 (11): 1251–1264.

https://doi.org/10.1182/blood.2022016937

Published: 2023

Journal Articles

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

Blood (2023) 141 (6): 609–619.

https://doi.org/10.1182/blood.2022017866

Published: 2023

Includes: Supplemental data

Journal Articles

Influence of Household Income on Health-Related Quality of Life in Children with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 11001–11003.

https://doi.org/10.1182/blood-2022-160336

Published: 2022

Journal Articles

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Blood (2022) 140 (Supplement 1): 2376–2377.

https://doi.org/10.1182/blood-2022-168139

Published: 2022

Journal Articles

Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Regina M. Myers, Kaitlin Devine, Yimei Li, Sophie Lawrence, Allison Barz Leahy, Hongyan Liu, Lauren Vernau, Colleen Callahan, Diane Baniewicz, Stephan Kadauke, Regina McGuire, Margaret A Cameron, Amanda M. DiNofia, Susan R. Rheingold, Richard Aplenc, Carl H June, Stephan A. Grupp, Lisa Wray, Shannon L. Maude

Blood (2021) 138 (Supplement 1): 474.

https://doi.org/10.1182/blood-2021-147299

Published: 2021

Journal Articles

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Blood (2021) 138 (Supplement 1): 167.

https://doi.org/10.1182/blood-2021-149477

Published: 2021

NARROW

Near Universal National Uptake of Dexrazoxane in the Real-World Setting Associated with Reduced Cardiac ICU Care Requirements in Pediatric Acute Myeloid Leukemia

Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)

Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123

Preinfusion Risk Factors for the Development of Severe Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Infusion in Pediatric Patients

In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing

Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform

Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents

Survival Disparities By Frontline Clinical Trial Enrollment Status for Treatment of Pediatric Acute Myeloid Leukemia

Comparative Effectiveness of Reinduction Approaches for Pediatric Relapsed Acute Myeloid Leukemia

Establishing Real-World Data-Driven Response Criteria in Pediatric Acute Myeloid Leukemia

Outcomes and Toxicities after Allogeneic Hematopoietic Cell Transplant for Remission Consolidation or Relapse Therapy after CD19 Chimeric Antigen Receptor T Cell Therapy in Children and Young Adults with Acute Lymphoblastic Leukemia

Racial and Ethnic Differences in Acuity and Cumulative Frontline Organ Toxicity at the Time of Relapse in Pediatric Acute Myeloid Leukemia

IL-10 Levels Differentially Regulate IFNg Signaling of CART19 and CART22

How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

Influence of Household Income on Health-Related Quality of Life in Children with Acute Myeloid Leukemia

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only